| scholarly article | Q13442814 |
| P356 | DOI | 10.1158/1078-0432.CCR-12-1359 |
| P698 | PubMed publication ID | 23340299 |
| P50 | author | Cristina Saura | Q57030750 |
| P2093 | author name string | Lajos Pusztai | |
| Stephen Chan | |||
| Ling-Ming Tseng | |||
| Christine E Horak | |||
| Guan Xing | |||
| David Liu | |||
| Ovidiu C Trifan | |||
| Rosanne Welcher | |||
| P433 | issue | 6 | |
| P921 | main subject | ixabepilone | Q11711607 |
| paclitaxel | Q423762 | ||
| biomarker | Q864574 | ||
| P304 | page(s) | 1587-1595 | |
| P577 | publication date | 2013-01-22 | |
| P1433 | published in | Clinical Cancer Research | Q332253 |
| P1476 | title | Biomarker analysis of neoadjuvant doxorubicin/cyclophosphamide followed by ixabepilone or Paclitaxel in early-stage breast cancer | |
| P478 | volume | 19 |
| Q90505119 | A 3-gene biomarker signature to predict response to taxane-based neoadjuvant chemotherapy in breast cancer |
| Q39141610 | A PAM50-Based Chemoendocrine Score for Hormone Receptor-Positive Breast Cancer with an Intermediate Risk of Relapse. |
| Q91744969 | A Qualitative Transcriptional Signature for Predicting Extreme Resistance of ER-Negative Breast Cancer to Paclitaxel, Doxorubicin, and Cyclophosphamide Neoadjuvant Chemotherapy |
| Q50128212 | CONCORD biomarker prediction for novel drug introduction to different cancer types |
| Q42182888 | Cancer cell-autonomous contribution of type I interferon signaling to the efficacy of chemotherapy |
| Q99571268 | Cancer gene expression profiles associated with clinical outcomes to chemotherapy treatments |
| Q52581589 | Chemical genomics reveals inhibition of breast cancer lung metastasis by Ponatinib via c-Jun. |
| Q52730051 | Compound A attenuates toll-like receptor 4-mediated paclitaxel resistance in breast cancer and melanoma through suppression of IL-8. |
| Q36111215 | Comprehensive comparison of molecular portraits between cell lines and tumors in breast cancer |
| Q89533213 | Downregulation of GPSM2 is associated with primary resistance to paclitaxel in breast cancer |
| Q38810389 | Effect of CH-35, a novel anti-tumor colchicine analogue, on breast cancer cells overexpressing the βIII isotype of tubulin. |
| Q34880376 | Epithelial-mesenchymal transition spectrum quantification and its efficacy in deciphering survival and drug responses of cancer patients. |
| Q35503492 | Evaluation of public cancer datasets and signatures identifies TP53 mutant signatures with robust prognostic and predictive value |
| Q92455774 | Evaluation of the 12-Gene Molecular Score and the 21-Gene Recurrence Score as Predictors of Response to Neo-adjuvant Chemotherapy in Estrogen Receptor-Positive, HER2-Negative Breast Cancer |
| Q61448092 | FLOating-Window Projective Separator (FloWPS): A Data Trimming Tool for Support Vector Machines (SVM) to Improve Robustness of the Classifier |
| Q92921171 | Flexible Data Trimming Improves Performance of Global Machine Learning Methods in Omics-Based Personalized Oncology |
| Q35933373 | Generation of an algorithm based on minimal gene sets to clinically subtype triple negative breast cancer patients. |
| Q47437905 | Genome-wide analysis of the three-way interplay among gene expression, estrogen receptor expression and chemotherapeutic sensitivity in breast cancer |
| Q29248638 | Genome-wide profiles of methylation, microRNAs, and gene expression in chemoresistant breast cancer |
| Q65001627 | High expression of class III β-tubulin in upper gastrointestinal cancer types. |
| Q38719315 | High levels of class III β-tubulin expression are associated with aggressive tumor features in breast cancer |
| Q35020412 | Luminal progenitor and fetal mammary stem cell expression features predict breast tumor response to neoadjuvant chemotherapy |
| Q37038455 | Neoadjuvant doxorubicin/cyclophosphamide followed by ixabepilone or paclitaxel in early stage breast cancer and evaluation of βIII-tubulin expression as a predictive marker. |
| Q97418214 | PDXGEM: patient-derived tumor xenograft-based gene expression model for predicting clinical response to anticancer therapy in cancer patients |
| Q47271622 | PP2A as the Main Node of Therapeutic Strategies and Resistance Reversal in Triple-Negative Breast Cancer. |
| Q55357247 | Probabilistic graphical models relate immune status with response to neoadjuvant chemotherapy in breast cancer. |
| Q36054418 | Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection. |
| Q36383626 | Response and survival of breast cancer intrinsic subtypes following multi-agent neoadjuvant chemotherapy |
| Q43809683 | Role of high mobility group A1 and body mass index in the prognosis of patients with breast cancer |
| Q39677335 | SPAG5 as a prognostic biomarker and chemotherapy sensitivity predictor in breast cancer: a retrospective, integrated genomic, transcriptomic, and protein analysis. |
| Q52621007 | Single drug biomarker prediction for ER- breast cancer outcome from chemotherapy. |
| Q37618855 | Systematically defining single-gene determinants of response to neoadjuvant chemotherapy reveals specific biomarkers |
| Q41233155 | Targeting of apoptotic pathways by SMAC or BH3 mimetics distinctly sensitizes paclitaxel-resistant triple negative breast cancer cells. |
| Q33630465 | The E2F4 prognostic signature predicts pathological response to neoadjuvant chemotherapy in breast cancer patients |
| Q35025984 | The significance of microscopic mass spectrometry with high resolution in the visualisation of drug distribution |
| Q35000651 | Tumor-infiltrating immune cell profiles and their change after neoadjuvant chemotherapy predict response and prognosis of breast cancer |
| Q86361461 | βIII-tubulin overexpression is linked to aggressive tumor features and shortened survival in clear cell renal cell carcinoma |
Search more.